Literature DB >> 11067649

Differences in attitudes, knowledge and use of economic evaluations in decision-making in The Netherlands. The Dutch results from the EUROMET Project.

J E Zwart-van Rijkom1, H G Leufkens, J J Busschbach, A W Broekmans, F F Rutten.   

Abstract

OBJECTIVE: To investigate differences in attitudes, knowledge and actual use of economic evaluations in different groups of decision-makers, and to compare the results from the Netherlands with the overall European results of the European Network on Methodology and Application of Economic Evaluation Techniques (EUROMET) project. DESIGN AND
SETTING: Members of the EUROMET group conducted interviews and surveys with politicians, regulators, hospital pharmacists and physicians in The Netherlands. Three approaches of investigation could be adopted: (i) a postal questionnaire survey, (ii) semi-structured interviews, and (iii) a focus-group approach. MAIN OUTCOME MEASURES AND
RESULTS: In the Netherlands, decision-makers generally have a positive attitude towards economic evaluations. Nevertheless, their actual use and knowledge of economic evaluations are still limited. Hospital pharmacists and regulators are more objective than physicians and politicians, who also base their judgements on other societal values. Hospital pharmacists and regulators have a greater knowledge of economic evaluations, and they use them more often than the other groups. Most decision-makers do not want to base their decisions strictly on a cost-effectiveness ranking alone. Our findings were similar to the findings in other European countries.
CONCLUSIONS: Decision-makers prefer to make their own broad comparisons of advantages and disadvantages, and do not base their decisions solely on a single summary measure.

Mesh:

Year:  2000        PMID: 11067649     DOI: 10.2165/00019053-200018020-00005

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  10 in total

1.  Toward a broader view of values in cost-effectiveness analysis of health.

Authors:  P Menzel; M R Gold; E Nord; J L Pinto-Prades; J Richardson; P Ubel
Journal:  Hastings Cent Rep       Date:  1999 May-Jun       Impact factor: 2.683

2.  Research into the use of health economics in decision making in the United Kingdom--Phase II. Is health economics 'for good or evil'?

Authors:  T Duthie; P Trueman; J Chancellor; L Diez
Journal:  Health Policy       Date:  1999-01       Impact factor: 2.980

3.  Clinical decision making: from theory to practice. Cost-effectiveness analysis. A conversation with my father.

Authors:  D M Eddy
Journal:  JAMA       Date:  1992-03-25       Impact factor: 56.272

4.  Clinical decision making: from theory to practice. What do we do about costs?

Authors:  D M Eddy
Journal:  JAMA       Date:  1990-09-05       Impact factor: 56.272

5.  Cost-effectiveness analysis: is it ethical?

Authors:  A Williams
Journal:  J Med Ethics       Date:  1992-03       Impact factor: 2.903

6.  Economic evaluation in support of national health policy: the case of The Netherlands.

Authors:  E Elsinga; F F Rutten
Journal:  Soc Sci Med       Date:  1997-08       Impact factor: 4.634

7.  Economic evaluation under managed competition: evidence from the U.K.

Authors:  M Drummond; J Cooke; T Walley
Journal:  Soc Sci Med       Date:  1997-08       Impact factor: 4.634

Review 8.  The role of economic appraisal in Denmark.

Authors:  A Alban
Journal:  Soc Sci Med       Date:  1994-06       Impact factor: 4.634

Review 9.  Current status of economic appraisal of health technology in the European Community: report of the network. The EC Network on the Methodology of Economic Appraisal of Health Technology.

Authors:  L Davies; D Coyle; M Drummond
Journal:  Soc Sci Med       Date:  1994-06       Impact factor: 4.634

10.  Incorporating societal concerns for fairness in numerical valuations of health programmes.

Authors:  E Nord; J L Pinto; J Richardson; P Menzel; P Ubel
Journal:  Health Econ       Date:  1999-02       Impact factor: 3.046

  10 in total
  18 in total

1.  Highly active antiretroviral therapy: pharmacoeconomic issues in the management of HIV infection.

Authors:  P Sendi; A J Palmer; A Gafni; M Battegay
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  A qualitative approach to the use of economic data in the selection of medicines for hospital formularies: a French survey.

Authors:  Hans-Martin Späth; Marie Charavel; Magali Morelle; Marie-Odile Carrere
Journal:  Pharm World Sci       Date:  2003-12

3.  Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal.

Authors:  Christopher Evans; Manouche Tavakoli; Bruce Crawford
Journal:  Health Care Manag Sci       Date:  2004-02

4.  The impact of using different tariffs to value EQ-5D health state descriptions: an example from a study of acute cough/lower respiratory tract infections in seven countries.

Authors:  Raymond Oppong; Billingsley Kaambwa; Jacqueline Nuttall; Kerenza Hood; Richard D Smith; Joanna Coast
Journal:  Eur J Health Econ       Date:  2011-11-05

Review 5.  The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine.

Authors:  Robert Welte; Caroline L Trotter; W John Edmunds; Maarten J Postma; Philippe Beutels
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 6.  Economic evaluations of healthcare programmes and decision making: the influence of economic evaluations on different healthcare decision-making levels.

Authors:  Marieke E van Velden; Johan L Severens; Annoesjka Novak
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

7.  Economic evidence at the local level : options for making it more useful.

Authors:  Kees van Gool; Gisselle Gallego; Marion Haas; Rosalie Viney; Jane Hall; Robyn Ward
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 8.  How contexts and issues influence the use of policy-relevant research syntheses: a critical interpretive synthesis.

Authors:  Kaelan A Moat; John N Lavis; Julia Abelson
Journal:  Milbank Q       Date:  2013-09       Impact factor: 4.911

9.  Increasing Access to Cognitive-Behavioural Therapy (CBT) for the Treatment of Mental Illness in Canada: A Research Framework and Call for Action.

Authors:  Krista A Payne; Gail Myhr
Journal:  Healthc Policy       Date:  2010-02

10.  The role of economic evaluation in the decision-making process of family physicians: design and methods of a qualitative embedded multiple-case study.

Authors:  Chantale Lessard; André-Pierre Contandriopoulos; Marie-Dominique Beaulieu
Journal:  BMC Fam Pract       Date:  2009-02-11       Impact factor: 2.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.